Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Mydecine Innovations Group Inc (MYCO.NE)

Mydecine Innovations Group Inc (MYCO.NE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 64,461
  • Shares Outstanding, K 162,763
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,567 K
  • 60-Month Beta 2.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade MYCO.NE with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.11
  • Most Recent Earnings $-0.08 on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance

Most Recent Stories

More News
Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs

Company aims to increase health equity by developing more accessible treatment modalities better suited for existing healthcare infrastructure...

MYCO.NE : 0.1400 (+3.70%)
OTC.VN : 0.345 (-1.43%)
MYCOF : 0.0106 (-38.37%)
U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

DENVER, June 17, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology...

MYCO.NE : 0.1400 (+3.70%)
OTC.VN : 0.345 (-1.43%)
MYCOF : 0.0106 (-38.37%)
Mydecine Provides Company Update; Welcomes New Board Member

DENVER, June 09, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a...

MYCO.NE : 0.1400 (+3.70%)
OTC.VN : 0.345 (-1.43%)
MYCOF : 0.0106 (-38.37%)
Mydecine Announces First Quarter 2022 Financial Results and Highlights

DENVER, May 16, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a...

MYCO.NE : 0.1400 (+3.70%)
OTC.VN : 0.345 (-1.43%)
MYCOF : 0.0106 (-38.37%)
American Billionaire Entrepreneurs Bet Millions on Psychedelics

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – May 10, 2022 – Billionaire Bob Parsons, the founder of GoDaddy, believes psychedelics can heal trauma. The Marine infantryman...

CYBN.NE : 0.5300 (+3.92%)
MYCO.NE : 0.1400 (+3.70%)
PYPL : 63.79 (+0.44%)
TSLA : 157.20 (-2.65%)
CYBN : 0.3789 (+2.18%)
MYCOF : 0.0106 (-38.37%)
NUMI.TO : 0.0700 (-6.67%)
NUMIF : 0.0518 (-4.07%)
ATAI : 2.14 (+3.38%)
ENVB : 0.9199 (-0.17%)
Why Psychedelics Could Soon Replace Antidepressants

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – April 13, 2022 – Anxiety disorders are the most common mental illness in the US, affecting approximately 40 million adults...

CYBN.NE : 0.5300 (+3.92%)
MMED.NE : 14.9000 (+9.48%)
MYCO.NE : 0.1400 (+3.70%)
SEEL : 0.3876 (-11.10%)
MNMD : 9.93 (+1.53%)
CMPS : 8.76 (+5.29%)
MYCOF : 0.0106 (-38.37%)
CYBN : 0.3789 (+2.18%)
Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update

MYCO-001 Smoking Cessation Clinical Trial Moves Forward Following Conditional IRB Approval Company Advances IP Portfolio With New Patent Applications...

MYCO.NE : 0.1400 (+3.70%)
OTC.VN : 0.345 (-1.43%)
Demand for Toad Venom Rises Along With the Booming Psychedelics Market

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – March 30, 2022 –  Depression and anxiety affect millions around the world and the venom of a toad is the latest  psychedelic...

MMED.NE : 14.9000 (+9.48%)
MYCO.NE : 0.1400 (+3.70%)
NUMI.TO : 0.0700 (-6.67%)
NUMIF : 0.0518 (-4.07%)
SEEL : 0.3876 (-11.10%)
MNMD : 9.93 (+1.53%)
MYCOF : 0.0106 (-38.37%)
CMPS : 8.76 (+5.29%)
Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study

Clinical trial programs advance to further assess psychedelic-assisted psychotherapy utilizing lead drug candidate MYCO-001...

MYCO.NE : 0.1400 (+3.70%)
OTC.VN : 0.345 (-1.43%)
MYCOF : 0.0106 (-38.37%)
Mydecine To Attend March Investor Conferences

Learn more about Mydecine’s clinical trials and drug development strategy by scheduling a meeting with management...

MYCO.NE : 0.1400 (+3.70%)
OTC.VN : 0.345 (-1.43%)
MYCOF : 0.0106 (-38.37%)

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point N/A
1st Resistance Point N/A
Last Price 0.1400
1st Support Level N/A
2nd Support Level N/A
3rd Support Level N/A

See More

52-Week High 0.2000
Fibonacci 61.8% 0.1752
Fibonacci 50% 0.1675
Fibonacci 38.2% 0.1598
Last Price 0.1400
52-Week Low 0.1350

See More

Business Summary

Mydecine Innovations Group Inc is a biopharma and life sciences company engaged in the research, drug development, and clinical trials of psilocybin products.

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar